Texas judge dismisses part of Eli Lilly and Novo Nordisk antitrust fight over compounded GLP-1 weight-loss drugs

Eli Lilly and Novo Nordisk scored a win in an antitrust dispute tied to compounded weight-loss medicines using GLP-1 ingredients, after a Texas judge dismissed claims that the drugmakers illegally blocked access to compounded GLP-1 products.

According to the report, the case centered on allegations that the companies took steps that interfered with patients’ ability to obtain compounded versions of GLP-1 drugs, which are marketed as weight-loss treatments. Compounded medications are custom-made by pharmacies, typically when approved commercial products are not used in the same way or when prescribers seek tailored dosing.

The dismissal means the plaintiffs’ claims described in the filing were rejected at the court level described in the coverage. The companies, both major sellers of GLP-1-based obesity and diabetes therapies, have faced sustained scrutiny from regulators and competitors over how compounders are allowed to operate and how commercial manufacturers communicate with regulators and pharmacies.

A key point in the dispute is the competition and access question. If compounded GLP-1 products were easier for patients to obtain through additional channels, plaintiffs argued it could undermine the commercial market for brand-name therapies. The companies’ position, as framed by the lawsuit narrative, appears to have been that their actions were lawful and related to protecting their products and regulatory standing.

The ruling also highlights a broader regulatory and legal challenge shaping the obesity-drug market. GLP-1 therapies have seen explosive demand in the United States, and that demand has coincided with shortages and heightened interest in alternative supply routes, including compounding.

Eli Lilly, whose GLP-1 franchise includes weight-management therapy, and Novo Nordisk, a leading manufacturer of GLP-1-based treatments, have both been prominent targets of competition concerns. Litigation around compounded versions tends to bring together antitrust arguments, trademark and patent considerations, and pharmacy and regulatory compliance issues, often with fast-moving court timelines.

The reported coverage did not provide, in the information available here, details on what specific portions of the case were dismissed, whether the plaintiffs can amend and refile, or the reasoning used by the judge. It also did not specify the parties’ next steps or any remaining claims that might still be pending.

For market watchers, the practical impact will depend on whether the dismissal narrows the plaintiffs’ theory of liability and whether other related claims continue to move through the courts. Companies in the GLP-1 supply chain, including brand manufacturers and compounding pharmacies, will likely watch closely for signs on how courts balance access to compounded medicines against enforcement by manufacturers.